Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MINOCYCLINE HCL

All products: not a benefit

Other products in the same Health Canada class (J01AA) — coverage varies; not interchangeable

  • Doxycycline hyclate (PMS-Doxycycline): general benefit, Not a benefit
  • Tetracycline (Tetracyn): general benefit, Not a benefit
  • Tigecycline (Tygacil): general benefit
  • Doxycycline (Apprilon): not a benefit

Minocin · DIN 02173514 · 50mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-12-10 — choose a marketed DIN from the same-category list.Discontinued 2012-12-10 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-12-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2012-12-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Minocin · DIN 02173514 Manufacturer: Stiefel Canada Inc.; listing date 2008-01-15 Health Canada: Cancelled post market since 2012-12-10 · brand MINOCIN · ATC J01AA08 MINOCYCLINE · form Capsule · route Oral · ingredients MINOCYCLINE (MINOCYCLINE HYDROCHLORIDE) 50 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Minocin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=34672 · Verify on the e-Formulary ↗ (DIN 02173514)

Source record
DIN 02173514: Minocin Raw flags: notABenefit=Y, sec3=Y Item: 081224021; group id 33; item number 0068; lccId None; manufacturer id STI Source form: Cap; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02173514 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=34672
Interchangeable products
Minocycline · DIN 02084090 · $0.5616
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2012-12-10 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:24 Tetracyclines) and how they are covered

Matched class: 08:12:24 Tetracyclines

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: TIGECYCLINE Some products covered without a code (check the product listing): DOXYCYCLINE HYCLATE, TETRACYCLINE 08:12:24 Tetracyclines

DOXYCYCLINE HYCLATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (2), Listed, not a benefit (1), General benefit (7) · strengths: 20mg, 100mg · Cap, Tab

TETRACYCLINE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

TIGECYCLINE

· 1 products · General benefit · strengths: 50mg/Vial · Pd for Inj-5mLVial Pk (Preservative-Free)

DOXYCYCLINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · MR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:24
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATION AND CLINICAL USES MINOCYCLINE (minocycline hydrochloride) may be indicated for the treatment of the following infections due to susceptible strains of the designated organisms: Gall bladder infections caused by Escherichia coli. Urinary tract infections: cystitis, gonorrhea, pyelonephritis caused by Escherichia coli, Proteus species, Klebsiella species, Enterobacter aerogenes, Neisseria gonorrhoeae. When penicillin is contraindicated, minocycline may be employed as an alternative drug in the treatment of anal and pharyngeal gonorrhea and syphilis. Skin and soft tissue infections: abscess, cellulitis, furunculosis, impetigo and pyoderma caused by: Staphylococcus epidermidis. Staphylococcus aureus, Streptococcus pyogenes, Proteus Page 2 of 30 species, Escherichia coli. Although tetracyclines are not the drugs of choice in any staphylococcal or streptococcal infection minocycline could be useful in circumstances where these organisms are shown to be resistant to other agents but sensitive to minocycline. Bacterial evaluation of clinical cases invo… https://pdf.hres.ca/dpd_pm/00053334.PDF PM date: September 27, 2019 Source product: MINOCYCLINE; DIN 02084090; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Minocin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026